Omicron: a chimera of two early SARS-CoV-2 lineages

Omicron: a chimera of two early SARS-CoV-2 lineages | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Letter Omicron: a chimera of two early SARS-CoV-2 lineages Chenglong Xiong, Xiuliang Liu, Jiasheng Xiong, Zhong Sun, Wei Hu, and 8 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1302993/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract The current global epidemiology of COVID-19 is now characterized by the emergence and rapid spread of the SARS-CoV-2 Omicron variant on a global scale 1 , 2 . Despite the variant’s prompt predominance, there remain knowledge gaps in its origin and evolution history 3 – 6 . Here, we show that Omicron lineage SARS-CoV-2 is characterized by the feature of chimera. It was generated by genomic recombination of two early PANGO lineages of SARS-CoV-2. In the recombination event, strains with medium or high circulating intensity like SARS-CoV-2/human/USA/COR-21-434196/2021 belonging to PANGO lineage BA.1 provided the fundamental genome and served as the major parents, while the rare lineage strains like SARS-CoV-2/human/IRN/Ir-3/2019 belonging to B.35, as the minor parents, hybridized their genomic fractions into the major genomes at position 21593-23118nt. This recombination event results in 22 amino acid residue substitutions for the variant of Omicron, including 16 in the pivotal RBD of the spike protein. These substitutions have led to some subtle variations in the spatial structure and the affinity to hACE2 receptor of the spike protein 7 , 8 , thereby raising concerns about the effectiveness of available vaccines and antibody therapeutics 9 – 12 . The global spread and explosive growth of the SARS-CoV-2 in human population increase opportunities for future recombination 13 – 15 . Figures Figure 1 Figure 2 Main Text The outbreak of the current coronavirus disease (COVID-19) occurred in late 2019 and quickly spread globally. It has posed a remarkable threat to public health around the world 16 , 17 . This pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the Betacoronavirus genus and is characterized by an unsegmented, positive-sense, single-stranded RNA genome 18 , 19 . It is known that SARS-CoV-2 is a genetically diverse group that mutates continuously leading to the emergence of multiple variants 9 , 10 , 15 . As new variants become more widespread, additional genetic markers emerge 12 , 14 . By determining the phyletic lineages of the SARS-CoV-2 genomic variants and those of the conserved regions in the accessory and spike proteins of all the SARS-related coronaviruses, research in the evolution of molecular pathways involved in emergence of pandemic is critical for the development of therapeutics and vaccines as well as the prevention of future zoonosis 9 , 10 , 13 . One tool for this purpose is the PANGO (Pangolin lineage) nomenclature by Rambaut et al which takes a granular approach to classify and describe viral evolution with detailed lineages; as evidence becomes available, classifications of variants will be revised to reflect the continuous evolution of circulating variants and their changing epidemiology 20 , 21 . Potential variants of concern (VOCs), variants of interest (VOIs) or variants under monitoring (VUMs) are regularly assessed based on the risk posed to global public health 22 . Following the identification of a novel variant in South Africa on 24 November 2021, WHO designated Omicron (clade GRA, PANGO lineage B.1.1.529 and descendants BA.1 and BA.2) as the fifth SARS-CoV-2 VOC two days later due to its large number of substitutions 2 , 4 . The variant has since spread to most countries. The current global epidemiology of SARS-CoV-2 is now characterized by the emergence and rapid spread of the Omicron variant on a global scale, continued decline in the prevalence of the previous Delta and other variants 1 . Despite its prompt predominance, there remain knowledge gaps in its origin and evolution, which has attracted people's interests and speculations 3 – 6 . Here, we propose that Omicron variant may be derived from recombination of two early PANGO lineages of SARS-CoV-2. We retrieved a total of 4,192 whole-length genomes of SARS-CoV-2 from EpiCoV TM database of Global Initiative on Sharing All Infuenza Data (GISAID) and SARS-CoV-2 data (NCBI). These genome sequences belong to 1,263 PANGO lineages, including 29 lineages of VOCs, VOIs, VUMs and formerly monitored variants (FMVs) according WHO’s Tracking SARS-CoV-2 variants ( https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ , accessed December 18, 2021), and are those with the earliest collection times within each PANGO lineage ( Extended Data 1 and 2 : Tab. S1 and S2 ). After quality control which is mainly assessed by the extent of sequencing completion, 2609 whole-length genomes of SARS-CoV-2 were used for the first round rapid screen ( Extended Data 3 , Genome sequence matrix 1 ), while the genome sequences involved in all putative recombination events identified by the first round screen were picked out for further verification ( Extended Data 4 , Genome sequence matrix 2 ). Taking SARS-CoV-2/human/USA/UT-UPHL-211211887190/2021 (Accession, OL920485) as the query genome sequence, recombination events were detected and verified by Recombination Detection Program (RDP) v4.101 23,24 and the SimPlot Program package 25 . We confirmed that at least one recombination event occurred in the origin and evolution history of Omicron variant of SARS-CoV-2. In this event, strains like SARS-CoV-2/human/USA/COR-21-434196/2021 (Accession, OL849989) belonging to PANGO lineage BA.1 provided the fundamental genome for VOC Omicron and served as its major parents, while strains like SARS-CoV-2/human/IRN/Ir-3/2019 (Accession, MW737421) belonging to PANGO lineage B.35, as the minor parents, hybridized the genomic fractions into the major genome at the position of 21593-23118 nt (Fig. 1 , Extended Data 5 : Fig. S1 ). From the perspective of encoding protein by the recombination fraction, it may have a profound impact on the pathogenicity and transmission potential of the novel variant, i.e., Omicron lineage of SARS-CoV-2. This fraction encodes 144-505 amino acid residues of SARS-CoV-2’s spike protein (S). As a result of the recombination, VOC Omicron did derived the substitutions of N211I, L212V, V213R, R214E, deletion215P, deletion216E, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, from the minor parent of SARS-CoV-2/human/IRN/Ir-3/2019-like strains, while the substitution of G/D339D may come from a back mutation after recombination. All these substitutions locate in the NTD (N-terminal domain, residues 18~330) and RBD (receptor-binding domain, residues 331~528) of the S1 subunit of spike protein 7 , 26 , 27 , and even up to 16 in RBD (Tab. 1 ). The consistency of amino acid residues encoded by VOC Omicron and its minor parent in the corresponding fraction, as well as the difference between it and the major parent, proved at the level of amino acids that the recombination event may have actually happened. It is known that SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions (including insertions and deletions) in the spike protein 7 , 8 , and then the recombination event alone leads to 22 of them. By checking the isolation frequency of BA.1 in the databases, it is a lineage with medium or high circulating intensity. There are 292,755 and 82,610 isolates in GISAID’s EpiCoV TM database and SARS-CoV-2 data of NCBI (both accessed January 13, 2022), accounting for 4.17% (292755/7022141) and 2.57% (82610/3218586) of the total isolates in the two databases, respectively, while B.35 is obviously a rare lineage, accounting for 0.0019% (130/7022141) and 0.0018% (59/3218586) respectively in the two databases, and its striking area is more limited to several countries such as United Kingdom, Iceland, Australia, USA, Jordan, Timor-Leste and New Zealand. Fig. 2 shows the temporal order and isolation frequency of the PANGO lineages involved in the recombination event and the VOCs, VOIs, VUMs and FMVs then. Interestingly, both major parent BA.1 and minor parent B.35 are lineages that emerged in the early outbreak of COVID-19. Considering the rapid transmission potential of lineage BA.1, which accounted for 71.9% of the isolating proportion in less than two months after the emergence, BA.1 cannot be the descendant but the parent of VOC Omicron. In fact, when investigating 5,100 genomes of BA.1 PANGO lineage SARS-CoV-2, we found these viruses were different from the major parent of recombination only at 346 amino acid residue (R vs. K) but fundamentally different from the index Omicron variants (Accessions, OL920485, OL901845, and OL902308), which indicated that BA.1 lineage should be the recombination parent of VOC Omicron rather than the descendant of it (Tab. 1 ). However, the recombination event for VOC Omicron did not occurred until recently. The reason may be that the circulating frequency of the lineage B.35 is too low and its striking area is too limited, which reduces the chance of recombination between it and other lineages of SARS-CoV-2. After all, the prerequisite for recombination is that no less than two lineages of viruses co-infect an individual simultaneously 28 , 29 , but the isolation frequency of the minor parent lineage B.35 is so rare that it hardly has the opportunity to infect an individual with a prior SARS-CoV-2 infection, and vice versa . Our study suggested that Omicron PANGO lineage SARS-CoV-2 is characterized by the feature of chimera. It was generated by genomic recombination of two early SARS-CoV-2 lineages in the coding sequence (CDS) of spike protein, and the recombination event results in 22 amino acid residue substitutions for the variant of Omicron, including 16 in the pivotal RBD. Spike protein is the most critical structural protein of SARS-CoVs, which is responsible for recognizing and binding to the surface receptors of host cells 26 , 27 , 30 . The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, thereby raising concerns about the effectiveness of available vaccines and antibody therapeutics 9 – 12 . Unfortunately, these concerns do not seem unreasonable. It has been reported that these substitutions have led to some subtle variations in the spatial structure and the affinity to hACE2 receptor of the spike protein 3 , 8 , 31 . More importantly, it has caused the immune escape of Omicron variant to the available vaccines and antibody therapeutics 11,32−34 . Recombination is proposed to be critical for coronavirus diversity and emergence of SARS-CoV-2, MERS-CoV, SARS-CoV (2002), and other zoonotic CoVs. It allows viruses to overcome selective pressure and adapt to new hosts and environments 35 – 37 . Viral recombination between different CoVs within animal populations may lead to the emergence of novel zoonotic CoVs that are lethal to humans 38 . Spike proteins are type I membrane glycoproteins with signal peptides used for receptor binding and play a crucial role in viral attachment, fusion and entry, being a target for development of antibodies, entry inhibitors and vaccines 39 , 40 . Recombination events in the evolutionary history of the spike protein have particular significance for the current pandemic. Studies comparing coronavirus strains that are closely related to SARS-CoV-2 have proposed that SARS-CoV-2 acquired the ability to infect human cells through recombination within the spike protein sequence 37 , 41 , 42 . The enrichment for recombination found at spike protein is in agreement with many other recently published works as well 37 , 41 , 43 , 44 . Undoubtedly, recombination may be occurring during infections in humans 36 , 45 . The global spread and explosive growth of the SARS-CoV-2 in human population has contributed additional mutational variability into this genome, increasing opportunities for future recombination. It has been reported that recombination among SARS-CoV-2 is associated with increased spread and severe disease, and has resulted in vaccine failure 41 , 46 . Thus, targeting the ability of the virus to recombine is a critical consideration for vaccine development in the ongoing SARS-CoV-2 pandemic as well as future animal and zoonotic CoVs. Declarations Acknowledgements This research was funded by the National Natural Science Foundation of China (Grant No. 81872673), the Three-Year Action Plan of Shanghai Public Health System Construction-Key Discipline Construction (2020-2022, No. GWV-10.1-XK03), and the Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022, GWV-10.1-XK23). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. We acknowledge the contributions of scientists and researchers from all over the world for depositing the genomes of SARS-CoV-2 in SARS-CoV-2 data (NCBI) and EpiCoV TM database of Global Initiative on Sharing All Infuenza Data (GISAID). Author contributions Conceived research and designed study: C.X., Q.J., Q.Z., Y.F., and M.C. Bioinformatic analyses: X.L., J.X., Z.S., J.H., and Y.W. Epidemiology analyses: J.X., W.H., and K.L. Interpreted Data: C.X., K.T., Q.J., Q.Z., and Y.F. First draft: C.X., X.L, and J.X. Revision: C.X., X.L, J.X., Z.S., W.H., J.H., Y.W., K.L., K.T., M.C., Q.Z., Y.F., and Q.J. Supervision: M.C., and Q.J. Competing interests The authors declare no competing interests. Additional information Correspondence and requests for materials should be addressed to Chenglong Xiong ( [email protected] ), Yi Feng ( [email protected] ), or Qi Zhao ( [email protected] ). The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication, but GISAID data access, if needed, requires registration. Peer review information We thanks the reviewers for their contribution to the peer review of this work. References 1 WHO, COVID-19 Weekly Epidemiological Update. Edition 75 18, 2022 (2022). 2 CDC, SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021. MMWR Morb Mortal Wkly Rep 70 1731 (2021). 3 Ma, W. et al. , Genomic perspectives on the emerging SARS-CoV-2 omicron variant. Genomics Proteomics Bioinformatics (2022). 4 Ferre, V. M. et al. , Omicron SARS-CoV-2 variant: What we know and what we don't. Anaesth Crit Care Pain Med 41 100998 (2021). 5 Tong, C., Shi, W., Zhang, A. & Shi, Z., Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant in South Africa. Travel Med Infect Dis 46 102252 (2021). 6 Kupferschmidt, K., Where did 'weird' Omicron come from? SCIENCE 374 1179 (2021). 7 Cameroni, E. et al. , Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. NATURE (2021). 8 A. J. Venkatakrishnan, P. A. P. J., Omicron variant of SARS-CoV-2 harbors a unique insertion mutation of putative viral or human genomic origin. Preprint December 10 (2021). 9 Bano, I., Sharif, M. & Alam, S., Genetic drift in the genome of SARS COV-2 and its global health concern. J MED VIROL 94 88 (2022). 10 Akram, F. et al. , Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review. J VIROL METHODS 300 114375 (2022). 11 Gharpure, R. et al. , Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States. EMERG INFECT DIS 28 35 (2022). 12 Araf, Y. et al. , Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J MED VIROL (2022). 13 Singh, D. & Yi, S. V., On the origin and evolution of SARS-CoV-2. EXP MOL MED 53 537 (2021). 14 Angeli, F., Spanevello, A., Reboldi, G., Visca, D. & Verdecchia, P., SARS-CoV-2 vaccines: Lights and shadows. EUR J INTERN MED 88 1 (2021). 15 Awadasseid, A., Wu, Y., Tanaka, Y. & Zhang, W., SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations. INT J BIOL SCI 17 97 (2021). 16 Zhou, P. et al. , A pneumonia outbreak associated with a new coronavirus of probable bat origin. NATURE 579 270 (2020). 17 Lu, R. et al. , Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. LANCET 395 565 (2020). 18 Shang, J. et al. , Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117 11727 (2020). 19 Jackson, C. B., Farzan, M., Chen, B. & Choe, H., Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23 3 (2022). 20 Rambaut, A. et al. , A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. NAT MICROBIOL 5 1403 (2020). 21 O'Toole, A. et al. , Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol 7 b64 (2021). 22 WHO, Tracking SARS-CoV-2 variants. (2021). 23 Martin, D. & Rybicki, E., RDP: detection of recombination amongst aligned sequences. BIOINFORMATICS 16 562 (2000). 24 Martin, D. P., Murrell, B., Golden, M., Khoosal, A. & Muhire, B., RDP4: Detection and analysis of recombination patterns in virus genomes. Virus Evol 1 v3 (2015). 25 Lole, K. S. et al. , Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination. J VIROL 73 152 (1999). 26 Wang, Q. et al. , Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. CELL 181 894 (2020). 27 Lan, J. et al. , Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. NATURE 581 215 (2020). 28 Soli, R., Kaabi, B., Barhoumi, M., Maktouf, C. & Ahmed, S. B., Bayesian phylogenetic analysis of the influenza-A virus genomes isolated in Tunisia, and determination of potential recombination events. MOL PHYLOGENET EVOL 134 253 (2019). 29 Savolainen-Kopra, C. & Blomqvist, S., Mechanisms of genetic variation in polioviruses. REV MED VIROL 20 358 (2010). 30 Walls, A. C. et al. , Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. CELL 181 281 (2020). 31 Wang, R., Chen, J. & Wei, G. W., Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America. J PHYS CHEM LETT 12 11850 (2021). 32 Lu, L. et al. , Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. CLIN INFECT DIS (2021). 33 Wang, Y. et al. , The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect 11 1 (2022). 34 Nemet, I. et al. , Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N Engl J Med (2021). 35 Perez-Losada, M., Arenas, M., Galan, J. C., Palero, F. & Gonzalez-Candelas, F., Recombination in viruses: mechanisms, methods of study, and evolutionary consequences. INFECT GENET EVOL 30 296 (2015). 36 Gribble, J. et al. , The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLOS PATHOG 17 e1009226 (2021). 37 Li, X. et al. , Emergence of SARS-CoV-2 through recombination and strong purifying selection. SCI ADV 6 (2020). 38 Li, C. X. et al. , A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. BIOMED PHARMACOTHER 146 112550 (2022). 39 Woo, P. C., Huang, Y., Lau, S. K. & Yuen, K. Y., Coronavirus genomics and bioinformatics analysis. Viruses 2 1804 (2010). 40 Tai, W. et al. , Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. CELL MOL IMMUNOL 17 613 (2020). 41 Patino-Galindo, J. A. et al. , Recombination and lineage-specific mutations linked to the emergence of SARS-CoV-2. GENOME MED 13 124 (2021). 42 Haddad, D. et al. , SARS-CoV-2: Possible recombination and emergence of potentially more virulent strains. PLOS ONE 16 e251368 (2021). 43 Wu, F. et al. , A new coronavirus associated with human respiratory disease in China. NATURE 579 265 (2020). 44 Bobay, L. M., O'Donnell, A. C. & Ochman, H., Recombination events are concentrated in the spike protein region of Betacoronaviruses. PLOS GENET 16 e1009272 (2020). 45 Yi, H., 2019 Novel Coronavirus Is Undergoing Active Recombination. CLIN INFECT DIS 71 884 (2020). 46 Kow, C. S., Merchant, H. A. & Hasan, S. S., Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK. J Infect 83 e14 (2021). Table Table 1 is available in the supplementary files section. Additional Declarations There is NO Competing Interest. Supplementary Files ExtendedData1Tab.S1.xlsx (xlsx): Information of VOCs, VOIs, VUMs and FMVs of SARS-CoV-2 retrieval form GISAID ExtendedData2Tab.S2.xlsx (xlsx): Information of PANGO lineages of SARS-CoV-2 retrieval form NCBI ExtendedData4Genomesequencematrix238SQ.txt (fasta): Genome sequence matrix 2 ExtendedData5Fig.S1.tif (tiff): Recombination event verified by SimPlot 3.5.1 program package ExtendedData3Genomesequencematrix12609SQ.rar (rar): Genome sequence matrix 1 Tab.1Aminoacidsubstitutionscorrespondingtotherecombinationfraction.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1302993","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Letter","associatedPublications":[],"authors":[{"id":79868828,"identity":"efc508eb-d31d-4dda-97c0-8dd266b5beda","order_by":0,"name":"Chenglong Xiong","email":"data:image/png;base64,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","orcid":"","institution":"School of Public Health, Fudan University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Chenglong","middleName":"","lastName":"Xiong","suffix":""},{"id":79868829,"identity":"6e66bef8-4a73-4287-a13a-01ab3d2738f7","order_by":1,"name":"Xiuliang Liu","email":"","orcid":"","institution":"Department of Epidemiology, School of Public Health, Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xiuliang","middleName":"","lastName":"Liu","suffix":""},{"id":79868830,"identity":"a1805137-bcda-40b9-a8fd-c83bf8f8b81f","order_by":2,"name":"Jiasheng Xiong","email":"","orcid":"","institution":"Department of Social Medicine, School of Public Health, Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jiasheng","middleName":"","lastName":"Xiong","suffix":""},{"id":79868831,"identity":"c21e99b8-92da-49f8-b4c7-283a1e8f2750","order_by":3,"name":"Zhong Sun","email":"","orcid":"","institution":"Universiti Putra Malaysia","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Zhong","middleName":"","lastName":"Sun","suffix":""},{"id":79868832,"identity":"1fcecf98-0a1d-418f-bef1-9d8ab23613e0","order_by":4,"name":"Wei Hu","email":"","orcid":"","institution":"Fudan university, Shanghai","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Wei","middleName":"","lastName":"Hu","suffix":""},{"id":79868833,"identity":"bea94957-2f6e-4ce4-99ea-03fb84dc123d","order_by":5,"name":"Jingjing Hu","email":"","orcid":"","institution":"Shanghai Pinnacles Medical Technology Co., Ltd","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jingjing","middleName":"","lastName":"Hu","suffix":""},{"id":79868834,"identity":"262c7366-bfc8-442a-a893-b906bc79f1af","order_by":6,"name":"Yuqian Wang","email":"","orcid":"","institution":"Department of Epidemiology, School of Public Health, Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yuqian","middleName":"","lastName":"Wang","suffix":""},{"id":79868835,"identity":"6495aa65-09d5-437c-be53-c3c98552f4c4","order_by":7,"name":"Kunyu Li","email":"","orcid":"","institution":"Department of Integrative Medicine and Neurobiology, School of Basic Medical Sciences; Institutes of Brain Science, Brain Science Collaborative Innovation Center, State Key Laboratory of Medical Neu","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Kunyu","middleName":"","lastName":"Li","suffix":""},{"id":79868836,"identity":"e50eb419-7683-4c36-97e8-2fdc5791ff2f","order_by":8,"name":"Karuppiah Thilakavathy","email":"","orcid":"","institution":"Universiti Putra Malaysia","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Karuppiah","middleName":"","lastName":"Thilakavathy","suffix":""},{"id":79868837,"identity":"2f8767e8-e0de-4684-8f42-586fe0904c53","order_by":9,"name":"Mingquan Chen","email":"","orcid":"","institution":"Department of Emergency, and Department of Infectious Diseases, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai, 200040, China","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Mingquan","middleName":"","lastName":"Chen","suffix":""},{"id":79868838,"identity":"173a17a4-972b-403f-bc87-776707cbd59b","order_by":10,"name":"Qi Zhao","email":"","orcid":"","institution":"Department of Social Medicine, School of Public Health, Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Qi","middleName":"","lastName":"Zhao","suffix":""},{"id":79868839,"identity":"09de7957-260d-452c-930a-03f6c3dfde8d","order_by":11,"name":"Yi Feng","email":"","orcid":"https://orcid.org/0000-0002-7156-6023","institution":"Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yi","middleName":"","lastName":"Feng","suffix":""},{"id":79868840,"identity":"a149f62a-8628-4a36-9559-f5461bd08291","order_by":12,"name":"Qingwu Jiang","email":"","orcid":"","institution":"Department of Epidemiology, School of Public Health, Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Qingwu","middleName":"","lastName":"Jiang","suffix":""}],"badges":[],"createdAt":"2022-01-27 14:05:58","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1302993/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1302993/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":17745263,"identity":"1612bd8d-0ac8-4124-921c-777ad7abd8fd","added_by":"auto","created_at":"2022-01-28 16:48:55","extension":"tif","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":113230,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePanel of information related to the recombination event\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eA, schematic sequence display for overview the recombination event(s) about the Omicron SARS-CoV-2 variants. B, the plot diagram checked by RDP method, shows the \u003cem\u003ep\u003c/em\u003e value of it. C, and D, split UPGMA trees of the fractions derived from major and minor parents. In parts B, C, and D, curve or sequence(s) in red, green, and blue are potential recombinants, the major and minor parents, respectively.\u003c/p\u003e","description":"","filename":"Fig.1XXXXXXXXXXXX.tif","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/4a5797a8a441bab2f240876f.tif"},{"id":17745414,"identity":"950fac46-0b78-401c-9524-099a6c3e0c33","added_by":"auto","created_at":"2022-01-28 16:51:55","extension":"tif","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":59822,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe temporal order and isolation frequency of the PANGO lineages involved in the recombination event and the VOCs, VOIs, VUMs and FMVs\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eThe dot area is calculated according to the natural logarithm of the isolate numbers within each PANGO lineage, and that of B.35 is used as a reference to show the proportion of others. The data derived from EpiCoV\u003csup\u003eTM\u003c/sup\u003e database of Global Initiative on Sharing All Infuenza Data (GISAID, accessed December 18, 2021). Dots in red, green, and blue are potential recombinants, the major and minor parents, respectively.\u003c/p\u003e","description":"","filename":"Fig.2XXXXXXXXXXXXXXX.tif","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/73d689bcf55319df5f356769.tif"},{"id":17804693,"identity":"6f1b4856-c06f-46dc-b394-a1818a8ff951","added_by":"auto","created_at":"2022-01-31 14:55:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":577534,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/b5e65cd8-5d36-43c8-bac8-140ebff619cc.pdf"},{"id":17745256,"identity":"868a7454-7ea2-42f5-9726-b8ab68aa1122","added_by":"auto","created_at":"2022-01-28 16:48:55","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":75779,"visible":true,"origin":"","legend":"(xlsx): Information of VOCs, VOIs, VUMs and FMVs of SARS-CoV-2 retrieval form GISAID","description":"","filename":"ExtendedData1Tab.S1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/861ade4c0fe3acdc216501a6.xlsx"},{"id":17745415,"identity":"716bb6a1-e904-4137-8c93-98d9262dd93f","added_by":"auto","created_at":"2022-01-28 16:51:55","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":180837,"visible":true,"origin":"","legend":"(xlsx): Information of PANGO lineages of SARS-CoV-2 retrieval form NCBI","description":"","filename":"ExtendedData2Tab.S2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/02ab16f6eace1294bd487db3.xlsx"},{"id":17745262,"identity":"21f769c9-420f-48d8-a8cb-ab7beff28871","added_by":"auto","created_at":"2022-01-28 16:48:55","extension":"txt","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":1135137,"visible":true,"origin":"","legend":"(fasta): Genome sequence matrix 2","description":"","filename":"ExtendedData4Genomesequencematrix238SQ.txt","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/00844f78fc8d2135fc9884ca.txt"},{"id":17745260,"identity":"4eb93ede-8f5b-4878-a75b-55ab59feccf8","added_by":"auto","created_at":"2022-01-28 16:48:55","extension":"tif","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":3388188,"visible":true,"origin":"","legend":"(tiff): Recombination event verified by SimPlot 3.5.1 program package","description":"","filename":"ExtendedData5Fig.S1.tif","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/b88995cc3445eae1ff05698b.tif"},{"id":17745259,"identity":"33c4c2e6-5a0b-43b8-b9dd-2ec2410e0c6b","added_by":"auto","created_at":"2022-01-28 16:48:55","extension":"rar","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":136185,"visible":true,"origin":"","legend":"(rar): Genome sequence matrix 1","description":"","filename":"ExtendedData3Genomesequencematrix12609SQ.rar","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/a0b0502b6ea083c3aea0b50c.rar"},{"id":17745258,"identity":"8c90ceb7-5c82-4199-bdb5-fb0d79b97519","added_by":"auto","created_at":"2022-01-28 16:48:55","extension":"docx","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":16751,"visible":true,"origin":"","legend":"","description":"","filename":"Tab.1Aminoacidsubstitutionscorrespondingtotherecombinationfraction.docx","url":"https://assets-eu.researchsquare.com/files/rs-1302993/v1/f7d942fc6aa0a7beb475afa6.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"Omicron: a chimera of two early SARS-CoV-2 lineages","fulltext":[{"header":"Main Text","content":"\u003cp\u003eThe outbreak of the current coronavirus disease (COVID-19) occurred in late 2019 and quickly spread globally. It has posed a remarkable threat to public health around the world\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. This pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the \u003cem\u003eBetacoronavirus\u003c/em\u003e genus and is characterized by an unsegmented, positive-sense, single-stranded RNA genome\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. It is known that SARS-CoV-2 is a genetically diverse group that mutates continuously leading to the emergence of multiple variants\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eAs new variants become more widespread, additional genetic markers emerge\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. By determining the phyletic lineages of the SARS-CoV-2 genomic variants and those of the conserved regions in the accessory and spike proteins of all the SARS-related coronaviruses, research in the evolution of molecular pathways involved in emergence of pandemic is critical for the development of therapeutics and vaccines as well as the prevention of future zoonosis\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. One tool for this purpose is the PANGO (Pangolin lineage) nomenclature by Rambaut et al which takes a granular approach to classify and describe viral evolution with detailed lineages; as evidence becomes available, classifications of variants will be revised to reflect the continuous evolution of circulating variants and their changing epidemiology\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. Potential variants of concern (VOCs), variants of interest (VOIs) or variants under monitoring (VUMs) are regularly assessed based on the risk posed to global public health\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eFollowing the identification of a novel variant in South Africa on 24 November 2021, WHO designated Omicron (clade GRA, PANGO lineage B.1.1.529 and descendants BA.1 and BA.2) as the fifth SARS-CoV-2 VOC two days later due to its large number of substitutions\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. The variant has since spread to most countries. The current global epidemiology of SARS-CoV-2 is now characterized by the emergence and rapid spread of the Omicron variant on a global scale, continued decline in the prevalence of the previous Delta and other variants\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. Despite its prompt predominance, there remain knowledge gaps in its origin and evolution, which has attracted people\u0026apos;s interests and speculations\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Here, we propose that Omicron variant may be derived from recombination of two early PANGO lineages of SARS-CoV-2.\u003c/p\u003e\n\u003cp\u003eWe retrieved a total of 4,192 whole-length genomes of SARS-CoV-2 from EpiCoV\u003csup\u003eTM\u003c/sup\u003e database of Global Initiative on Sharing All Infuenza Data (GISAID) and SARS-CoV-2 data (NCBI). These genome sequences belong to 1,263 PANGO lineages, including 29 lineages of VOCs, VOIs, VUMs and formerly monitored variants (FMVs) according WHO\u0026rsquo;s Tracking SARS-CoV-2 variants (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.who.int/en/activities/tracking-SARS-CoV-2-variants/\u003c/span\u003e\u003c/span\u003e, accessed December 18, 2021), and are those with the earliest collection times within each PANGO lineage (\u003cstrong\u003eExtended Data 1 and 2\u003c/strong\u003e: \u003cstrong\u003eTab. S1\u003c/strong\u003e and \u003cstrong\u003eS2\u003c/strong\u003e). After quality control which is mainly assessed by the extent of sequencing completion, 2609 whole-length genomes of SARS-CoV-2 were used for the first round rapid screen (\u003cstrong\u003eExtended Data 3\u003c/strong\u003e, \u003cstrong\u003eGenome sequence matrix 1\u003c/strong\u003e), while the genome sequences involved in all putative recombination events identified by the first round screen were picked out for further verification (\u003cstrong\u003eExtended Data 4\u003c/strong\u003e, \u003cstrong\u003eGenome sequence matrix 2\u003c/strong\u003e). Taking SARS-CoV-2/human/USA/UT-UPHL-211211887190/2021 (Accession, OL920485) as the query genome sequence, recombination events were detected and verified by Recombination Detection Program (RDP) v4.101\u003csup\u003e23,24\u003c/sup\u003e and the SimPlot Program package\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eWe confirmed that at least one recombination event occurred in the origin and evolution history of Omicron variant of SARS-CoV-2. In this event, strains like SARS-CoV-2/human/USA/COR-21-434196/2021 (Accession, OL849989) belonging to PANGO lineage BA.1 provided the fundamental genome for VOC Omicron and served as its major parents, while strains like SARS-CoV-2/human/IRN/Ir-3/2019 (Accession, MW737421) belonging to PANGO lineage B.35, as the minor parents, hybridized the genomic fractions into the major genome at the position of 21593-23118 nt (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e, \u003cstrong\u003eExtended Data 5\u003c/strong\u003e: \u003cstrong\u003eFig. S1\u003c/strong\u003e). From the perspective of encoding protein by the recombination fraction, it may have a profound impact on the pathogenicity and transmission potential of the novel variant, i.e., Omicron lineage of SARS-CoV-2. This fraction encodes 144-505 amino acid residues of SARS-CoV-2\u0026rsquo;s spike protein (S). As a result of the recombination, VOC Omicron did derived the substitutions of N211I, L212V, V213R, R214E, deletion215P, deletion216E, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, from the minor parent of SARS-CoV-2/human/IRN/Ir-3/2019-like strains, while the substitution of G/D339D may come from a back mutation after recombination. All these substitutions locate in the NTD (N-terminal domain, residues 18~330) and RBD (receptor-binding domain, residues 331~528) of the S1 subunit of spike protein\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e, and even up to 16 in RBD (Tab. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). The consistency of amino acid residues encoded by VOC Omicron and its minor parent in the corresponding fraction, as well as the difference between it and the major parent, proved at the level of amino acids that the recombination event may have actually happened. It is known that SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions (including insertions and deletions) in the spike protein\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e, and then the recombination event alone leads to 22 of them.\u003c/p\u003e\n\u003cp\u003eBy checking the isolation frequency of BA.1 in the databases, it is a lineage with medium or high circulating intensity. There are 292,755 and 82,610 isolates in GISAID\u0026rsquo;s EpiCoV\u003csup\u003eTM\u003c/sup\u003e database and SARS-CoV-2 data of NCBI (both accessed January 13, 2022), accounting for 4.17% (292755/7022141) and 2.57% (82610/3218586) of the total isolates in the two databases, respectively, while B.35 is obviously a rare lineage, accounting for 0.0019% (130/7022141) and 0.0018% (59/3218586) respectively in the two databases, and its striking area is more limited to several countries such as United Kingdom, Iceland, Australia, USA, Jordan, Timor-Leste and New Zealand. Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e shows the temporal order and isolation frequency of the PANGO lineages involved in the recombination event and the VOCs, VOIs, VUMs and FMVs then.\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003eInterestingly, both major parent BA.1 and minor parent B.35 are lineages that emerged in the early outbreak of COVID-19. Considering the rapid transmission potential of lineage BA.1, which accounted for 71.9% of the isolating proportion in less than two months after the emergence, BA.1 cannot be the descendant but the parent of VOC Omicron. In fact, when investigating 5,100 genomes of BA.1 PANGO lineage SARS-CoV-2, we found these viruses were different from the major parent of recombination only at 346 amino acid residue (R \u003cem\u003evs.\u003c/em\u003e K) but fundamentally different from the index Omicron variants (Accessions, OL920485, OL901845, and OL902308), which indicated that BA.1 lineage should be the recombination parent of VOC Omicron rather than the descendant of it (Tab. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). However, the recombination event for VOC Omicron did not occurred until recently. The reason may be that the circulating frequency of the lineage B.35 is too low and its striking area is too limited, which reduces the chance of recombination between it and other lineages of SARS-CoV-2. After all, the prerequisite for recombination is that no less than two lineages of viruses co-infect an individual simultaneously\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e, but the isolation frequency of the minor parent lineage B.35 is so rare that it hardly has the opportunity to infect an individual with a prior SARS-CoV-2 infection, and \u003cem\u003evice versa\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003eOur study suggested that Omicron PANGO lineage SARS-CoV-2 is characterized by the feature of chimera. It was generated by genomic recombination of two early SARS-CoV-2 lineages in the coding sequence (CDS) of spike protein, and the recombination event results in 22 amino acid residue substitutions for the variant of Omicron, including 16 in the pivotal RBD. Spike protein is the most critical structural protein of SARS-CoVs, which is responsible for recognizing and binding to the surface receptors of host cells\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e27\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, thereby raising concerns about the effectiveness of available vaccines and antibody therapeutics\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Unfortunately, these concerns do not seem unreasonable. It has been reported that these substitutions have led to some subtle variations in the spatial structure and the affinity to hACE2 receptor of the spike protein\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. More importantly, it has caused the immune escape of Omicron variant to the available vaccines and antibody therapeutics\u003csup\u003e11,32\u0026minus;34\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eRecombination is proposed to be critical for coronavirus diversity and emergence of SARS-CoV-2, MERS-CoV, SARS-CoV (2002), and other zoonotic CoVs. It allows viruses to overcome selective pressure and adapt to new hosts and environments\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e35\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e. Viral recombination between different CoVs within animal populations may lead to the emergence of novel zoonotic CoVs that are lethal to humans\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e. Spike proteins are type I membrane glycoproteins with signal peptides used for receptor binding and play a crucial role in viral attachment, fusion and entry, being a target for development of antibodies, entry inhibitors and vaccines\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e39\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. Recombination events in the evolutionary history of the spike protein have particular significance for the current pandemic. Studies comparing coronavirus strains that are closely related to SARS-CoV-2 have proposed that SARS-CoV-2 acquired the ability to infect human cells through recombination within the spike protein sequence\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e. The enrichment for recombination found at spike protein is in agreement with many other recently published works as well\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e43\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eUndoubtedly, recombination may be occurring during infections in humans\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e36\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e. The global spread and explosive growth of the SARS-CoV-2 in human population has contributed additional mutational variability into this genome, increasing opportunities for future recombination. It has been reported that recombination among SARS-CoV-2 is associated with increased spread and severe disease, and has resulted in vaccine failure\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e. Thus, targeting the ability of the virus to recombine is a critical consideration for vaccine development in the ongoing SARS-CoV-2 pandemic as well as future animal and zoonotic CoVs.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research was funded by the National Natural Science Foundation of China (Grant No. 81872673), the Three-Year Action Plan of Shanghai Public Health System Construction-Key Discipline Construction (2020-2022, No. GWV-10.1-XK03), and the Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2020-2022, GWV-10.1-XK23). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. We acknowledge the contributions of scientists and researchers from all over the world for depositing the genomes of SARS-CoV-2 in SARS-CoV-2 data (NCBI) and EpiCoV\u003csup\u003eTM\u003c/sup\u003e database of Global Initiative on Sharing All Infuenza Data (GISAID).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConceived research and designed study: C.X., Q.J., Q.Z., Y.F., and M.C. Bioinformatic analyses: X.L., J.X., Z.S., J.H., and Y.W. Epidemiology analyses: J.X., W.H., and K.L. Interpreted Data: C.X., K.T., Q.J., Q.Z., and Y.F. First draft: C.X., X.L, and J.X. Revision: C.X., X.L, J.X., Z.S., W.H., J.H., Y.W., K.L., K.T., M.C., Q.Z., Y.F., and Q.J. Supervision: M.C., and Q.J.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdditional information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCorrespondence and requests for materials should be addressed to Chenglong Xiong (\u003ca href=\"mailto:[email protected]\"\[email protected]\u003c/a\u003e), Yi Feng (\u003ca href=\"mailto:[email protected]\"\[email protected]\u003c/a\u003e), or Qi Zhao (\u003ca href=\"mailto:[email protected]\"\[email protected]\u003c/a\u003e). The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication, but GISAID data access, if needed, requires registration.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePeer review information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe thanks the reviewers for their contribution to the peer review of this work.\u003c/p\u003e"},{"header":"References","content":"\u003cp\u003e\u003csup\u003e\u0026nbsp;1\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;WHO, COVID-19 Weekly Epidemiological Update. \u003cstrong\u003eEdition 75\u003c/strong\u003e 18, 2022 (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp;2\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;CDC, SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021. \u003cem\u003eMMWR Morb Mortal Wkly Rep\u003c/em\u003e \u003cstrong\u003e70\u003c/strong\u003e 1731 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp;3\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Ma, W.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Genomic perspectives on the emerging SARS-CoV-2 omicron variant. \u003cem\u003eGenomics Proteomics Bioinformatics\u003c/em\u003e (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp;4\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Ferre, V. M.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Omicron SARS-CoV-2 variant: What we know and what we don\u0026apos;t. \u003cem\u003eAnaesth Crit Care Pain Med\u003c/em\u003e \u003cstrong\u003e41\u003c/strong\u003e 100998 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp;5\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Tong, C., Shi, W., Zhang, A. \u0026amp; Shi, Z., Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant \u0026nbsp;in South Africa. \u003cem\u003eTravel Med Infect Dis\u003c/em\u003e \u003cstrong\u003e46\u003c/strong\u003e 102252 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp;6\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Kupferschmidt, K., Where did \u0026apos;weird\u0026apos; Omicron come from? \u003cem\u003eSCIENCE\u003c/em\u003e \u003cstrong\u003e374\u003c/strong\u003e 1179 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp;7\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Cameroni, E.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. \u003cem\u003eNATURE\u003c/em\u003e (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp;8\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;A. J. Venkatakrishnan, P. A. P. J., Omicron variant of SARS-CoV-2 harbors a unique insertion mutation of putative viral or human genomic origin. \u003cem\u003ePreprint\u003c/em\u003e \u003cstrong\u003eDecember\u0026nbsp;\u003c/strong\u003e10 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e\u0026nbsp;9\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Bano, I., Sharif, M. \u0026amp; Alam, S., Genetic drift in the genome of SARS COV-2 and its global health concern. \u003cem\u003eJ MED VIROL\u003c/em\u003e \u003cstrong\u003e94\u003c/strong\u003e 88 (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e10\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Akram, F.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review. \u003cem\u003eJ VIROL METHODS\u003c/em\u003e \u003cstrong\u003e300\u003c/strong\u003e 114375 (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e11\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Gharpure, R.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States. \u003cem\u003eEMERG INFECT DIS\u003c/em\u003e \u003cstrong\u003e28\u003c/strong\u003e 35 (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e12\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Araf, Y.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. \u003cem\u003eJ MED VIROL\u003c/em\u003e (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e13\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Singh, D. \u0026amp; Yi, S. V., On the origin and evolution of SARS-CoV-2. \u003cem\u003eEXP MOL MED\u003c/em\u003e \u003cstrong\u003e53\u003c/strong\u003e 537 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e14\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Angeli, F., Spanevello, A., Reboldi, G., Visca, D. \u0026amp; Verdecchia, P., SARS-CoV-2 vaccines: Lights and shadows. \u003cem\u003eEUR J INTERN MED\u003c/em\u003e \u003cstrong\u003e88\u003c/strong\u003e 1 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e15\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Awadasseid, A., Wu, Y., Tanaka, Y. \u0026amp; Zhang, W., SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations. \u003cem\u003eINT J BIOL SCI\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e 97 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e16\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Zhou, P.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, A pneumonia outbreak associated with a new coronavirus of probable bat origin. \u003cem\u003eNATURE\u003c/em\u003e \u003cstrong\u003e579\u003c/strong\u003e 270 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e17\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Lu, R.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. \u003cem\u003eLANCET\u003c/em\u003e \u003cstrong\u003e395\u003c/strong\u003e 565 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e18\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Shang, J.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Cell entry mechanisms of SARS-CoV-2. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e \u003cstrong\u003e117\u003c/strong\u003e 11727 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e19\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Jackson, C. B., Farzan, M., Chen, B. \u0026amp; Choe, H., Mechanisms of SARS-CoV-2 entry into cells. \u003cem\u003eNat Rev Mol Cell Biol\u003c/em\u003e \u003cstrong\u003e23\u003c/strong\u003e 3 (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e20\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Rambaut, A.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. \u003cem\u003eNAT MICROBIOL\u003c/em\u003e \u003cstrong\u003e5\u003c/strong\u003e 1403 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e21\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;O\u0026apos;Toole, A.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. \u003cem\u003eVirus Evol\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e b64 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e22\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;WHO, Tracking SARS-CoV-2 variants. (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e23\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Martin, D. \u0026amp; Rybicki, E., RDP: detection of recombination amongst aligned sequences. \u003cem\u003eBIOINFORMATICS\u003c/em\u003e \u003cstrong\u003e16\u003c/strong\u003e 562 (2000).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e24\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Martin, D. P., Murrell, B., Golden, M., Khoosal, A. \u0026amp; Muhire, B., RDP4: Detection and analysis of recombination patterns in virus genomes. \u003cem\u003eVirus Evol\u003c/em\u003e \u003cstrong\u003e1\u003c/strong\u003e v3 (2015).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e25\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Lole, K. S.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination. \u003cem\u003eJ VIROL\u003c/em\u003e \u003cstrong\u003e73\u003c/strong\u003e 152 (1999).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e26\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Wang, Q.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. \u003cem\u003eCELL\u003c/em\u003e \u003cstrong\u003e181\u003c/strong\u003e 894 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e27\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Lan, J.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. \u003cem\u003eNATURE\u003c/em\u003e \u003cstrong\u003e581\u003c/strong\u003e 215 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e28\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Soli, R., Kaabi, B., Barhoumi, M., Maktouf, C. \u0026amp; Ahmed, S. B., Bayesian phylogenetic analysis of the influenza-A virus genomes isolated in Tunisia, and determination of potential recombination events. \u003cem\u003eMOL PHYLOGENET EVOL\u003c/em\u003e \u003cstrong\u003e134\u003c/strong\u003e 253 (2019).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e29\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Savolainen-Kopra, C. \u0026amp; Blomqvist, S., Mechanisms of genetic variation in polioviruses. \u003cem\u003eREV MED VIROL\u003c/em\u003e \u003cstrong\u003e20\u003c/strong\u003e 358 (2010).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e30\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Walls, A. C.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. \u003cem\u003eCELL\u003c/em\u003e \u003cstrong\u003e181\u003c/strong\u003e 281 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e31\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Wang, R., Chen, J. \u0026amp; Wei, G. W., Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America. \u003cem\u003eJ PHYS CHEM LETT\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e 11850 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e32\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Lu, L.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. \u003cem\u003eCLIN INFECT DIS\u003c/em\u003e (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e33\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Wang, Y.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. \u003cem\u003eEmerg Microbes Infect\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e 1 (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e34\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Nemet, I.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. \u003cem\u003eN Engl J Med\u003c/em\u003e (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e35\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Perez-Losada, M., Arenas, M., Galan, J. C., Palero, F. \u0026amp; Gonzalez-Candelas, F., Recombination in viruses: mechanisms, methods of study, and evolutionary consequences. \u003cem\u003eINFECT GENET EVOL\u003c/em\u003e \u003cstrong\u003e30\u003c/strong\u003e 296 (2015).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e36\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Gribble, J.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, The coronavirus proofreading exoribonuclease mediates extensive viral recombination. \u003cem\u003ePLOS PATHOG\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e e1009226 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e37\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Li, X.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Emergence of SARS-CoV-2 through recombination and strong purifying selection. \u003cem\u003eSCI ADV\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e38\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Li, C. X.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. \u003cem\u003eBIOMED PHARMACOTHER\u003c/em\u003e \u003cstrong\u003e146\u003c/strong\u003e 112550 (2022).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e39\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Woo, P. C., Huang, Y., Lau, S. K. \u0026amp; Yuen, K. Y., Coronavirus genomics and bioinformatics analysis. \u003cem\u003eViruses\u003c/em\u003e \u003cstrong\u003e2\u003c/strong\u003e 1804 (2010).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e40\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Tai, W.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: \u0026nbsp;implication for development of RBD protein as a viral attachment inhibitor and vaccine. \u003cem\u003eCELL MOL IMMUNOL\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e 613 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e41\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Patino-Galindo, J. A.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, Recombination and lineage-specific mutations linked to the emergence of SARS-CoV-2. \u003cem\u003eGENOME MED\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e 124 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e42\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Haddad, D.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, SARS-CoV-2: Possible recombination and emergence of potentially more virulent strains. \u003cem\u003ePLOS ONE\u003c/em\u003e \u003cstrong\u003e16\u003c/strong\u003e e251368 (2021).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e43\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Wu, F.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e, A new coronavirus associated with human respiratory disease in China. \u003cem\u003eNATURE\u003c/em\u003e \u003cstrong\u003e579\u003c/strong\u003e 265 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e44\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Bobay, L. M., O\u0026apos;Donnell, A. C. \u0026amp; Ochman, H., Recombination events are concentrated in the spike protein region of Betacoronaviruses. \u003cem\u003ePLOS GENET\u003c/em\u003e \u003cstrong\u003e16\u003c/strong\u003e e1009272 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e45\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Yi, H., 2019 Novel Coronavirus Is Undergoing Active Recombination. \u003cem\u003eCLIN INFECT DIS\u003c/em\u003e \u003cstrong\u003e71\u003c/strong\u003e 884 (2020).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e46\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Kow, C. S., Merchant, H. A. \u0026amp; Hasan, S. S., Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK. \u003cem\u003eJ Infect\u003c/em\u003e \u003cstrong\u003e83\u003c/strong\u003e e14 (2021).\u003c/p\u003e"},{"header":"Table","content":"\u003cp\u003eTable 1 is available in the supplementary files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-1302993/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1302993/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe current global epidemiology of COVID-19 is now characterized by the emergence and rapid spread of the SARS-CoV-2 Omicron variant on a global scale\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Despite the variant\u0026rsquo;s prompt predominance, there remain knowledge gaps in its origin and evolution history\u003csup\u003e\u003cspan additionalcitationids=\"CR4 CR5\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Here, we show that Omicron lineage SARS-CoV-2 is characterized by the feature of chimera. It was generated by genomic recombination of two early PANGO lineages of SARS-CoV-2. In the recombination event, strains with medium or high circulating intensity like SARS-CoV-2/human/USA/COR-21-434196/2021 belonging to PANGO lineage BA.1 provided the fundamental genome and served as the major parents, while the rare lineage strains like SARS-CoV-2/human/IRN/Ir-3/2019 belonging to B.35, as the minor parents, hybridized their genomic fractions into the major genomes at position 21593-23118nt. This recombination event results in 22 amino acid residue substitutions for the variant of Omicron, including 16 in the pivotal RBD of the spike protein. These substitutions have led to some subtle variations in the spatial structure and the affinity to hACE2 receptor of the spike protein\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e, thereby raising concerns about the effectiveness of available vaccines and antibody therapeutics\u003csup\u003e\u003cspan additionalcitationids=\"CR10 CR11\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. The global spread and explosive growth of the SARS-CoV-2 in human population increase opportunities for future recombination\u003csup\u003e\u003cspan additionalcitationids=\"CR14\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e","manuscriptTitle":"Omicron: a chimera of two early SARS-CoV-2 lineages","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-01-28 16:48:53","doi":"10.21203/rs.3.rs-1302993/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"099209e5-7328-4019-bcbe-449763e5e0ff","owner":[],"postedDate":"January 28th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2022-01-31T18:36:19+00:00","versionOfRecord":[],"versionCreatedAt":"2022-01-28 16:48:53","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1302993","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1302993","identity":"rs-1302993","version":["v1"]},"buildId":"FbvkV6FR0MCFSLy54lSbu","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}